Blar i forfatter "von Plessen, Christian"

Viser treff 1-5 av 5

    • Adverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care 

      Haukland, Ellinor Christin; von Plessen, Christian; Nieder, Carsten; Vonen, Barthold (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-06-01)
      <i>Background</i> - Anticancer treatment exposes patients to negative consequences such as increased toxicity and decreased quality of life, and there are clear guidelines recommending limiting use of aggressive anticancer treatments for patients near end of life. The aim of this study is to investigate the association between anticancer treatment given during the last 30 days of life and adverse ...

    • Adverse events in hospitalised cancer patients: a comparison to a general hospital population 

      Haukland, Ellinor Christin; von Plessen, Christian; Nieder, Carsten; Vonen, Barthold (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-04-05)
      <p><i>Background</i>: Patients with cancer are often treated by many healthcare providers, receive complex and potentially toxic treatments that can increase the risk for iatrogenic harm. The aim of this study is to investigate whether hospitalised cancer patients are at higher risk of adverse events (AEs) compared to a general hospital population.</p> <p><i>Material and methods</i>: A total of ...

    • Contribution of adverse events to death of hospitalised patients 

      Haukland, Ellinor Christin; Mevik, Kjersti; von Plessen, Christian; Nieder, Carsten; Vonen, Barthold (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-02-13)
      <i>Background</i> - There is no standardised method to investigate death as a patient safety indicator and we need valid and reliable measurements to use adverse events contributing to death as a quality measure.<p> <p><i>Objective</i> - To investigate the contribution of severe adverse events to death in hospitalised patients and clarify methodological differences using the Global Trigger Tool ...

    • Does chemotherapy improve Quality of Life in NSCLC PS 2? 

      Sundstrøm, Stein H.; Helbekkmo, Nina; von Plessen, Christian; Strøm, Hans H.; Aasebø, Ulf; Bremnes, Roy M. (Journal article; Tidsskriftartikkel; Peer reviewed, 2009-03)
      Introduction <br>Nearly 40% of patients with advanced NSCLC are in performance status (PS) 2. These patients have a shorter life expectancy than PS 0/1 patients and they are underrepresented in clinical trials. Data on how platinum-based combination chemotherapy affects Health Related Quality of Life (HRQOL) of patients with PS 2 are scarce and the treatment of this important group of patients is ...

    • Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group 

      Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M.; Amundsen, Tore; Sundstrøm, Stein Harald; Rolke, Heidi; HORNSLIEN, KJERSTI; Wentzel-Larsen, Tore; Aasebø, Ulf; von Plessen, Christian (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-07-03)
      BACKGROUND: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a platinum combination.<p> <p>METHODS: Eligible patients had stage IIIB/IV NSCLC ...